The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030>>::

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs
Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”
The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

A detailed review of the current landscape of companies offering contract manufacturing services.

Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.

A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.

An analysis of the partnerships and expansions that have been established in this domain, in the recent past.

A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.

A detailed proprietary 2×2 representation to assess the current market scenario

An analysis of the initiatives of big biopharma players engaged in this domain.

  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Product
API
FDF
Type of Biologic
  • Proteins
  • Enzymes
  • Growth Hormones
  • Antibody based Drugs
  • Others (plasmid DNA, probiotics, microbiome-based biologics)
  • Type of Microbial Expression System
  • Bacteria
  • Yeast
  • Others (Algae and fungi)
Scale of Operation
Commercial
Preclinical / Clinical
Type of End User
Small Companies
Mid-sized Companies
Large / Very Large Companies
Key Geographical Regions
North America
Europe
Asia Pacific
Middle East and North Africa
Latin America
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Key companies covered in the report
  • AGC Biologics
  • Aldevron
  • BioVectra
  • EirGenix
  • Etinpro
  • Eurogentec
  • Northway Biotechpharma
  • Ology Bioservices
  • Porton Biopharma
  • Stelis Biopharma


For additional details, please visit

https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email [email protected]

You may also be interested in the following titles:
Contact:
Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]
 
 

 

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
1311 Posts

Made with by Mamby